SCOTUS to hear biosimilar clash between Amgen and Sandoz

25-04-2017

SCOTUS to hear biosimilar clash between Amgen and Sandoz

renaschild / iStockphoto.com

The US Supreme Court will hear oral arguments from Sandoz and Amgen tomorrow, when the battle over a biosimilar of Amgen’s Neupogen (filgrastim) will resume.


Amgen, Sandoz, biologics, biosimilars, patent, Neupogen, Zarxio, FDA, BPCIA, SCOTUS, patent dance

More on this story

SCOTUS hears Amgen v Sandoz biosimilar dispute
27-04-2017

LSIPR